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Immune responses to lung infections must be tightly regulated in order to permit pathogen 
eradication while maintaining organ function. Exuberant or dysregulated inflammation 
can impair gas exchange and underlies many instances of lung disease. An important 
driver of inflammation in the lung is the interferon (IFN) response. Type I IFNs are antiviral 
cytokines that induce a large range of proteins that impair viral replication in infected 
cells. This cell-intrinsic action plays a crucial role in protecting the lungs from spread of 
respiratory viruses. However, type I IFNs have also recently been found to be central to 
the initiation of lung inflammatory responses, by inducing recruitment and activation of 
immune cells. This helps control virus burden but can cause detrimental immunopathol-
ogy and contribute to disease severity. Furthermore, there is now increasing evidence 
that type I IFNs are not only induced after viral infections but also after infection with 
bacteria and fungi. The pro-inflammatory function of type I IFNs in the lung opens up 
the possibility of immune modulation directed against this antiviral cytokine family. In 
this review, the initiation and signaling of type I IFNs as well as their role in driving and 
maintaining lung inflammation will be discussed.
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LUNG iNFLAMMATiON
Mucosal surfaces such as those found in the intestine and the lungs are the most common targets 
for invading pathogens. The surface area of the human lung is approximately 70 m2, and its main 
function is gas exchange (1). The lung is constantly in direct contact with the environment and the 
cells of the lung need to be able to tolerate non-harmful stimuli but react appropriately to harmful 
pathogens. When lung cells respond to invading pathogens, the regulation of inflammation is par-
ticularly important since the lung comprises delicate structure crucial for conducting gas exchange.
Interferons (IFNs), discovered in the 1950s, represent a family of cytokines, which induce robust 
antiviral and immunomodulatory responses to interfere with virus replication and spread (2–4). 
IFNs can be classified into three main subclasses: type I, II, and III. Type I IFNs consist of several 
IFN-α isoforms (13 in human and 14 in mice), IFN-β, IFN-ɛ, IFN-κ, and IFN-ω. In contrast, type 
II IFNs include only one member, IFN-γ. The most recently discovered group of IFNs are the type 
III IFNs, including IFN-λ1 (IL-29; non-functional pseudogene in mice), IFN-λ2 (IL-28A), IFN-λ3 
(IL-28B), and the very recently described human IFN-λ4 (5–7). This review will focus on the role of 
type I IFNs in the lung, however, many of the effects induced by type I IFNs will also be mediated 
by the other types of IFNs.
Sensing of pathogen-associated molecular patterns (PAMPs) by pattern recognition recep-
tors (PRRs) results in production of many cytokines and chemokines including the type I IFNs. 
These cytokines have a whole array of functions. First, they elicit an antiviral state in infected and 
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neighboring, uninfected cells. Second, type I IFNs modulate the 
immune response by promoting antigen presentation, cytokine 
production, dendritic cell (DC) and natural killer (NK) cell activ-
ity, and macrophage function. Third, they enhance the adaptive 
immune response by manipulating T cell effector function and 
antibody production. Overall, the antiviral and immune stimula-
tory potential of type I IFNs is required for the effective clearance 
of acute viral infections (2–4, 8). Furthermore, the impact of type 
I IFNs on the inflammatory response during other types of infec-
tions is also starting to be appreciated.
iNDUCTiON OF TYPe i iFNs
Multiple cell types including leukocytes and structural cells 
can detect PAMPs, in various cellular compartments and in 
all tissues. Recognition of PAMPs by the PRRs initiates an 
intracellular signaling cascade that causes the translocation of 
transcription factors to the nucleus initiating innate immune 
gene expression. The PRRs that can couple pathogen detection 
to type I IFN induction are toll-like receptors (TLRs), retinoic 
acid-inducible gene I (RIG)-I-like receptors (RLRs), and cGAS/
cGAMP/stimulator of IFN genes [stimulator of interferon genes 
(STING); Figure 1].
The endosomally expressed TLRs that induce type I IFN gene 
expression are TLR-3, -7, -8, and -9, each of which detects differ-
ent forms of nucleic acids (14). TLR3 recognizes double-stranded 
(ds) RNA which initiates the TRIF-dependent signaling cascade 
(15). TLR-7/8 and -9 recognize GU-rich single-stranded (ss) RNA 
and unmethylated CpG DNA, respectively (9), and they require 
MyD88 for their signaling. Finally, one cell surface expressed 
TLR, TLR4, which recognize lipopolysaccharides (LPS), and 
respiratory syncytial virus (RSV) F protein (16), can induce type 
I IFNs via TRIF-mediated signaling (15) (Figure 1).
The three receptors in the RLRs family, RIG-I, melanoma 
differentiation-associated protein 5 (MDA5), and laboratory of 
genetics and physiology 2 (LGP2) detect viral RNA in the cytosol 
(10, 11). Due to their localization within the cytoplasm, these 
receptors are constantly exposed to host RNA, and it is therefore 
important to distinguish it from that of viral origin. For this rea-
son, the receptors can detect features that are common in many 
viral genomes and viral replication intermediates but absent 
from the host (12). RIG-I specifically binds to short uncapped 
5′-triphosphate (5′-ppp) and 5′-diphosphate (5′-pp)-bearing 
base-paired RNA molecules, an RNA motif known to be present 
in some viral genomes but not in host RNA (17–19). MDA5 binds 
long stretches of base-paired RNA, which, again, are absent from 
uninfected cells but often produced as a consequence of viral 
replication (11). Structurally, RIG-I and MDA5 share many 
similarities as they both have caspases activation and recruitment 
domains (CARDs) essential for the downstream signaling (10, 
11). LGP2 possesses the RNA-binding domain but it lacks the 
CARD domains and is therefore not involved in direct signaling. 
Instead, a role for LGP2 in assisting MDA5-mediated signaling 
has been suggested (20). For both RIG-I and MDA5, binding of 
agonists allows downstream signaling through the adaptor mol-
ecule mitochondrial antiviral signaling protein (MAVS), leading 
to the activation of NF-κB and IRF3 and subsequent induction 
of gene expression of various antiviral mediators including type I 
IFNs (11, 21, 22) (Figure 1).
The first DNA sensor described was DNA-dependent activator 
of IFN-regulatory factors (DAI), which was shown to induce type 
I IFNs during in vitro infections of fibroblast with either herpes 
simplex virus 1 or cytomegalovirus (CMV). However, the in vivo 
role for DAI remains unclear (23). Another pathway of recognizing 
infections with DNA viruses is via RNA polymerase III (PolIII), 
which transforms DNA into a 5′-ppp RNA, the ligand for RIG-I, 
yet the physiological role of PolIII remains elusive (24, 25). Other 
proteins belonging to the PYHIN (IFI16; IFN gamma-inducible 
protein 16, and AIM2; absent in melanoma 2) or DExD/H-box 
helicase (DDX) protein families were suggested likely DNA 
sensors, but their specific role in  vivo is unclear and is being 
investigated [(26); for an extensive review about DNA sensing, see 
Ref. (24)]. The discovery of the adaptor protein STING identified 
a pathway crucial for the recognition of foreign dsDNA in vivo. 
Located at the endoplasmic reticulum, STING activates signaling 
via NF-κB and IRF3, resulting in the production of type I IFNs 
(27) (Figure 1). Recently, guanosine-monophosphate adenosine-
monophosphate (cyclic GMP-AMP or cGAMP) synthase (cGAS) 
was identified as a DNA sensor leading to the downstream activa-
tion of STING. cGAS binds dsDNA and catalyzes the synthesis of 
the second messenger cGAMP from ATP and GTP, which binds 
to STING and activates the signaling cascade leading to type I IFN 
production (28–30). Interestingly, cGAMP can be transferred 
through gap junctions from infected cell to neighboring cells and 
thereby spread antiviral immunity (31).
Different cells of the lung will respond differently to infec-
tions depending on both the tropism of the pathogen (which 
cells that are infected) and which PRRs that are triggered. Lung 
epithelial cells are the first and most abundant cell type that will 
interact with the pathogens, and they have the ability to induce 
IFN-β production especially after influenza virus infection (32). 
In addition, plasmacytoid dendritic cells (pDCs) have a consti-
tutive expression of IRF-7, which make them able to respond 
rapidly to TLR7 ligation and induce type I IFNs (33). This is 
especially important during influenza virus infection (34). 
However, during RSV infection, it is the alveolar macrophages 
(AMs) that are the major source of type I IFNs and they use 
MAVS-dependent PRRs for sensing the virus (35). Thus, in the 
lung as well as on other sites, many different pathogens can be 
recognized by several sets of PRRs expressed on the cell surface, 
in endosomes, or in the cytosol by different cell types. In com-
bination, this will result in the induction of type I IFNs and an 
efficient antiviral response.
SiGNALiNG THROUGH THe TYPe i  
iFN ReCePTOR
Type I IFNs bind to the heterodimeric transmembrane IFN-α/β 
receptor (IFNAR), which is expressed on all nucleated cells 
and composed of the two subunits: IFNAR1 and IFNAR2 (36) 
(Figure 2). Via signaling through the Janus kinase (JAK)/signal 
transducer and activator of transcription (STAT) pathway, the 
induction of several hundreds of interferon stimulated genes 
(ISGs) is initiated (36–40) (Figure  2). These ISGs interfere 
FiGURe 1 | Pattern recognition receptor signaling that leads to the induction of type i interferons (iFNs). The endosomally expressed TLR-3, -7, -8, and 
-9, cell surface expressed TLR4, the RLRs [retinoic acid-inducible gene I (RIG)-I and MDA-5], and cGAMP synthase (cGAS) can couple pathogen detection to type I 
IFN induction. TLR3 and TLR4 signal via TRIF, which occurs through inhibitor of kappa-B (IκB) kinases (IKKs), tumor necrosis factor (TNF) receptor-associated factor 
(TRAF) family associated NF-κB activator (TANK)-binding kinase-1 (TBK1), and IKK-ɛ. This causes the activation of IRF3, which in turn induces the expression of 
type I IFNs. The activation of TLR3 can also induce the production of inflammatory mediators via TRIF by activating a complex formed by TRAF-6, TNF receptor type 
I DEATH domain-associated protein (TRADD), Pellino-1, and the receptor-interacting kinase (RIP)-1. This causes the activation of NF-κB pathway, which is mediated 
by the IKK complex and transforming growth factor beta activated kinase (TAK)-1. TLR7, 8, and 9 use MyD88 for downstream signaling and can activate IRF and 
NF-κB pathways. RIG-I and MDA5 signal through the adaptor molecule mitochondrial antiviral signaling protein (MAVS). cGAS signals via the adaptor protein 
stimulator of interferon genes (STING). MAVS and STING further recruit signaling molecules (involving the IKK complex, TBK1, and several TRAF proteins) and lead 
to the activation of NF-κB and IRF3, resulting in gene expression of various antiviral cytokines including type I IFNs (9–13).
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with various stages of the viral cycle and change the state of the 
infected and neighboring cells. Type I IFN signaling also drive 
the immune response to a number of pathogens by, for example, 
enhancing the production of inflammatory mediators, cell com-
munication, and the induction of apoptosis in infected cells (see 
below). It is interesting that the type I IFN receptor has so many 
ligands, and it is still unclear if all type I IFNs bind the receptor in 
the same way or if binding of certain IFNs results in a functional 
difference. There is evidence that different IFNs bind to different 
anchor points resulting in variations to the binding affinities and 
conformational change of the IFNAR1 (41). In addition, IFN-β 
can ligate only the subunit IFNAR1 and signal independently of 
JAK–STAT pathways (42). Type I IFN production and signaling 
are tightly regulated by a positive feedback loop, with early IFNs 
(in the mouse IFN-β and IFN-α4) stimulating the expression of 
the ISG IRF7 and other important signaling molecules (43). This 
regulates the expression of all IFN-α isotypes (44) resulting in 
enhanced signaling through the type I IFN receptor (Figure 2). 
While the positive feedback loop is important for enhancing the 
production and effect of type I IFNs, equally important are the 
negative regulators that are required to restore cellular homeo-
stasis. The type I IFN response is tightly controlled by a series 
of mechanism that are dependent on cell-intrinsic factors, ISG-
mediated proteins, and miRNA. The activity of STAT proteins can 
FiGURe 2 | Type i interferon (iFN) signaling. Type I IFNs bind to the heterodimeric transmembrane IFN-α/β receptor (IFNAR), which is composed of the two 
subunits: IFNAR1 and IFNAR2. The c-termini of IFNAR1 and IFNAR2 are associated with the tyrosine kinase 2 (TYK2) and Janus kinase 1 (JAK1), respectively, and 
activation of the receptor transduces the phosphorylation of JAK1 and TYK2 by tyrosine phosphorylation. This initiates a signaling cascade composed of proteins of 
the signal transducer and activator of transcription (STAT) family. The STAT1 and STAT2 proteins are activated upon JAK1 phosphorylation, dimerize and together 
with IRF9, form the ISG factor 3 (ISGF3) complex. This complex translocates to the nucleus and binds to IFN-stimulated response elements (ISREs) in interferon-
stimulated genes (ISGs) promoters to initiate gene transcription. Signaling through IFNAR can also occur independent of IRF9 recruitment through STAT1 
homodimers that can bind to IFN-γ-activated sites (GAS) in ISG promoters. Both pathways initiate transcription that promotes the induction of a range of 
pro-inflammatory mediators and enhance the antiviral state. The JAK–TYK signaling pathway can also promote signaling pathways independent of STAT signaling. 
One such pathway includes MAPKs, which are important for signals regulating important cellular functions such as gene transcription, post-transcription, apoptosis, 
and cell-cycle progression. Specifically, the p38 signaling cascade after IFN-stimulation drives transcription of genes that are important for inducing the antiviral 
effects of type I IFNs and are regulated by ISREs and GAS. Further to MAPK, the type I IFN receptor signaling can also activate the phosphoinositide 3-kinase (PI3K) 
signaling pathway. The phosphorylation of PI3K causes the activation of the RAC-α serine/threonine-protein kinase (AKT1)/cAMP responsive-element-binding 
protein that can bind smad binding elements (SBE). This signaling pathway is believed to be important for transcription of genes controlling cellular survival and 
inflammatory (36, 38–40).
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be regulated by protein inhibitors of activated STAT (PIAS) and 
the suppressor of cytokine proteins (SOCS). Another important 
ISG for the regulation of type I IFN signaling is the ubiquitin 
carbol-terminal hydrolase protein, USP18 (40, 45).
Type I IFN responses are difficult to study in humans since by 
the time patients with severe lower respiratory tract infections are 
likely to be admitted to hospital several days have passed since 
the initial infection, at which time the production of type I IFNs 
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is declining and not easily detectable. However, it is interesting 
that complete type I IFN deficiency has not been described in 
humans but mutations in STAT1, tyrosine kinase 2, or NEMO are 
associated with poor control of viral infections (46, 47). Recently, 
a mutation in IRF7, leading to impaired type I and type III IFN 
responses, was shown to result in severe influenza infection in 
one case (48). In addition, severe RSV disease has been associated 
with polymorphisms in several innate immune response genes, in 
particular many that control the type I IFN system (49, 50). Also, 
several ISGs have been associated with severe influenza infection 
in mouse and man, for example, IFITM3 and MX1 (51–54). 
Thus, most data suggest an important role for type I IFNs during 
respiratory infections.
TYPe i iFNs DRiviNG LUNG 
iNFLAMMATiON
The type I IFN signaling is especially important for the control 
of viral infections. However, in many diseases, the usefulness of 
type I IFNs has been debated (55). Like all immune responses, a 
balance is required and launching a response is as important as 
dampening it. As type I IFNs can lead to both cellular recruitment 
and activation, an imbalance of the type I IFN response can influ-
ence the cellular responses to either result in immunosuppression 
or immunopathology.
Type I IFNs have multiple effects in the lung. They have been 
shown to result in the production of chemokines such as CCL2, 
a monocyte chemoattractant, and CXCL10, important for the 
recruitment of monocytes/macrophages, T  cells, NK  cells, and 
DCs, therefore directly influencing inflammation in the lung (35, 
56–58). The type I IFNs also drive a multitude of events in DCs 
including the differentiation of precursors, increased antigen 
presentation and cross-presentation, expression of costimulatory 
molecules, and promoting chemokine secretion and migration 
(8, 59–66). Interestingly, different subsets of DCs have a different 
degree of sensitivity to type I IFN signaling, which determines the 
susceptibility to influenza virus infection and thereby how much 
antigen they can present (67). Type I IFNs are also important for 
the activation of macrophages and NK cells (8, 68). Also, CD4+ 
and CD8+ T cells are directly affected by type I IFNs during vari-
ous infections and the effect of type I IFNs can either be stimula-
tory or inhibitory by stimulating proliferation, differentiation, 
survival as well as inducing anti-proliferative and pro-apoptotic 
responses (63, 69). Type I IFN receptor signaling in T  cells is 
also important for cytokine secretion, cytotoxicity, and memory 
formation (63). This varied effect of type I IFNs on T  cells is 
partly dependent on the different STATs induced by type I IFNs 
where for example STAT1 is pro-inflammatory, pro-apoptotic, 
and anti-proliferative, while STAT4 promotes proliferation and 
cell survival (63). The different effects are dependent on when 
and where the T cells get the signal via the type I IFN receptor 
and will therefore be dependent on the site of infection, timing, 
magnitude, and source of type I IFN responses. B cells are also 
influenced by type I IFNs, and type I IFN receptor signaling on 
both B and T cells is important for antibody production (70, 71). 
Interestingly, it has been suggested that during LCMV infection, 
type I IFN receptor signaling in CD8+ T cells increase their killing 
of B cells and therefore decrease the production of neutralizing 
antibodies (72). If this is also occurring during respiratory infec-
tions remain to be elucidated.
In the absence of type I IFNs, there is often less inflammation in 
the lung. Interestingly, intranasal administration of IFN-α alone 
can stimulate the expression of pro-inflammatory cytokines (56, 
73). Also, IFN-α can potentiate the pro-inflammatory responses 
after intranasal LPS challenge (56). How this occurs considering 
most cytokines and chemokines are induced by NF-κβ and not 
IFNAR signaling is unknown. One possibility is the fact that type 
I IFNs increase the expression of many PRRs or related signaling 
molecules, which can enhance signaling via other pathways for 
example those involved in NF-κB activation (74). Nevertheless, 
all cellular components involved in the mutual influence of 
NF-κB and type I IFN pathways are not fully investigated and 
might depend on the cellular context. It is therefore a likely sce-
nario that type I IFNs play a role in NF-κB-induced expression of 
pro-inflammatory cytokines and chemokines.
Lung viral infections
Type I IFNs are rapidly produced during all lung viral infections 
and contribute to the initial control of viral replication before 
effective innate and adaptive cellular responses are generated 
to clear the virus. Signaling via the IFNAR activates a cascade 
of ISGs that directly interfere with viral replication and viral 
spread. These include proteins that inhibit virus entry (e.g., 
MX1, IFITM proteins, TRIM proteins), modulate membrane 
lipids to prevent viral release (e.g., Viperin, Tetherin), induce 
apoptosis of infected cells [e.g., protein kinase R (PKR)], regu-
late transcriptional (e.g., Viperin) and posttranscriptional (e.g., 
OAS/RNaseL, PKR) mechanisms, and posttranslational events 
(e.g., ISG15) (38, 40). In addition to the ISG-mediated effects, 
type I IFNs modulate cell viability and function (e.g., apoptosis, 
inhibiting cell death, differentiation, migration, proliferation) to 
support antiviral defense (75). The amplification of the primary 
signal by type I IFNs is achieved by upregulation of many PRR 
molecules and associated signaling molecules like TLR3, RIG-I, 
MDA5, MAVS, MyD88, IRF3, and IRF7, which are themselves 
ISGs and therefore amplify the type I IFN response to viral infec-
tions [see above and Ref. (76, 77)]. Without a functioning IFNAR 
loop the detection of accumulating viral RNA and the further 
downstream processing of the signal is compromised in infected 
cells as they lack the feedback-mediated boosted expression of 
the viral RNA sensors. This imbalance will eventually promote 
viral replication and spread early during infection and also 
influence the degree of inflammation. For example, in a severe 
acute respiratory syndrome-CoV infection, type I IFN induc-
tion is delayed resulting in an overwhelming viral burden (78). 
Interestingly, many viruses have virulence factors that antagonize 
type I IFN responses [reviewed elsewhere (79–81)], indicating 
the importance of type I IFN responses during viral infection. It 
is also important to note that, especially during influenza virus 
infection, type III IFNs (IFN-λ) are highly induced at the same 
time as type I IFNs (82, 83). Interestingly, the receptor for IFN-λ is 
mostly expressed by epithelial cells and therefore these cytokines 
have a more restricted effect directed to intrinsic antiviral mecha-
nisms (73). The effects of IFN-λ have recently been reviewed (5).
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There are also age-related effects of type I IFN production in 
response to respiratory infections as both cells from infants and 
neonatal mice show a reduced type I IFN production and ISG 
induction after RSV exposure (84–86). Furthermore, monocytes 
from elderly have a diminished type I IFN response after expo-
sure to influenza virus (53). Interestingly, these age groups are 
also very vulnerable to respiratory infections.
In addition to the cell-intrinsic responses, type I IFNs are 
known to enhance immune responses especially by activating 
and recruiting immune cells. During RSV infection, type I IFNs 
produced by AMs, induced the production of CCL2 and other 
chemoattractants crucial for monocyte extravasation into the 
lung during RSV infection (35). These recruited monocytes 
are important for controlling the virus (35). Interestingly, the 
expression of pro-inflammatory cytokines and chemokines 
was significantly reduced in RSV, influenza virus, and human 
metapneumovirus-infected Ifnar1−/− mice (56, 87, 88). This high-
lights again a synergizing effect of NF-κB and type I IFN pathways 
in inducing the optimal secretion of cytokines and chemokines. 
However, NF-κB translocation into the nucleus can be detected 
as early as 0.5 h post RSV inoculation without the necessity of 
viral replication (89). This might provide an explanation for the 
early induction of some of the measured cytokines such as IFN-β, 
IL-6, TNF-α, or IL-12 in the lungs of RSV-infected Ifnar1−/− mice, 
but perhaps sustained NF-κB activation may be in part type I 
IFN dependent. In contrast to Ifnar1−/− mice, wt mice have the 
ability to further enhance this “first signal” through the IFNAR-
driven autocrine and paracrine amplification loop to maximize 
the responses. Moreover, the lack of responsiveness to viruses in 
Ifnar1−/− mice could also suppress the recruitment of additional 
cells to the site of infection, which could otherwise contribute 
to local cytokine secretion. These usually specifically recruited 
cells are most likely of non-polymorphonuclear origin, since 
neutrophil recruitment was comparable or increased in RSV or 
influenza virus infected Ifnar1−/− mice compared to wt mice (56, 
90). Furthermore, during influenza or Sendai virus infection type 
I IFNs can act as messengers from the lung to the bone marrow 
where they instruct leukocytes to activate an antiviral transcrip-
tional program, resulting in an increased antiviral state of these 
cells before they migrate to the lung (91).
Additional to T cell expansion, type I IFNs have been shown 
to promote T effector cell function due to the dependence on 
IFNAR mediated STAT1 signaling for the cytolytic activity of 
memory CD8+ T  cells during recall responses with respiratory 
viruses (92). In contrast, after influenza virus infection type I 
IFNs can induce the secretion of IL-10 from CD8+ T cells (93) 
and the expression of programmed cell death ligand 1 (PDL-1) on 
epithelial cells (94). Furthermore, blocking of PDL-1 enhanced 
CD8+ T cells function and viral clearance (94). Thus, type I IFNs 
are important both to induce T cell effector functions and also 
to induce anti-inflammatory mechanisms that can suppress the 
T cell response.
Despite the essential role for type I IFNs in activating the 
immune response to successfully combat viral infection and to 
guarantee survival of the organism, they can have deleterious 
effects on the host and cause acute immunopathology. High type 
I IFN production during influenza virus infection mediated by 
recruited inflammatory monocytes and pDCs cause the upregu-
lation of TNF-related apoptosis-inducing ligand (TRAIL) (8, 95). 
This “death” ligand binds to the death receptor 5 on epithelial 
cells, the expression of which is also upregulated by type I IFNs. 
Thus, the TRAIL-expressing inflammatory monocytes cause the 
death of the epithelial cells, which in turn increases morbidity or 
death of the mice (83, 96). Therefore, the potential of type I IFNs 
to drive and amplify pro-inflammatory responses (56, 83) could, 
if type I IFNs are produced excessively or for an extended time, 
cause the increased morbidity and mortality during lung viral 
infections (78, 83, 96). Thus, the timing and magnitude of type 
I IFN responses are crucial to obtain an efficient cell-intrinsic 
response and a balanced cell-extrinsic response that together 
lead to the clearance of the virus without causing detrimental 
immunopathology.
Lung Bacterial infections
Since type I IFNs have an important role in preventing replication 
and spread during viral infections their role is overall beneficial. 
During lung bacterial infections, type I IFNs are induced but 
the role of these cytokines is unclear and their ability to drive 
inflammation might in these cases be more detrimental. For 
example, mice deficient in IFNAR1 or TLR9 showed an improved 
clearance of Staphylococcus aureus (97). Also, a lung infection 
model of Chlamydia trachomatis mouse pneumonitis (Chlamydia 
muridarum) showed that deficiency in the IFNAR1 resulted in 
less bacterial burden and bodyweight loss, and milder pathologi-
cal changes (98). Mycobacterium tuberculosis (MTb) infection of 
TB-susceptible Ifnar1−/− mice showed enhanced protection from 
death, lower bacterial burden in the lungs, and decreased degree 
of lung inflammation compared to wt mice (99). In addition, an 
interferon signature is evident in patients with active MTb disease 
(100), and mouse studies have shown that the type I IFN responses 
during MTb infection is tightly regulated by IL-1 and PGE2 (101). 
More contradictory data are presented for Streptococcus pneumo-
niae infection, where an invasive strain of S. pneumoniae induces 
type I IFNs in the lungs and blocking the IFNAR decreased the 
systemic bacteremia (102). In contrast, another study showed 
that S. pneumoniae infection of Ifnar1−/− mice or mice treated 
with an antibody against the type I IFN receptor displayed 
enhanced bacterial spread and increase bacteremia (103). In 
addition, if mice were given rIFN-β, this reduced the bacteremia 
after intranasal S. pneumoniae infection (103). Thus, most data 
suggest that type I IFNs induced during lung bacterial infection 
are part of the inflammatory response and might be important to 
initiate immune responses to the infection. However, since these 
cytokines lead to the recruitment and activation of immune cells, 
this can enhance inflammation and result in bacterial dissemina-
tion and spread.
Interestingly, bacterial secondary infections are common after 
a severe lung viral infection and the host is more susceptible to 
infection by Escherichia coli, Pseudomonas aeruginosa, S. pneumo-
niae, or S. aureus after influenza virus infection (104–106). This 
increased susceptibility is probably due to many factors such as a 
lower activation threshold of lung cells, inhibition of important 
signaling pathways and cytokines induction and exhaustion of 
immune cells resulting in non-appropriate immune responses 
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elicited to the new pathogen. Noteworthy, this increased suscep-
tibility cease to exist as soon as the virus-induced type I IFNs are 
decreasing (104) and IFNAR1 deficient mice can effectively clear 
a secondary S. pneumoniae infection (106). Furthermore, the 
induction of type I IFNs during influenza virus infection attenu-
ates chemokines important for neutrophil recruitment, which 
can promote secondary bacterial pneumonia (107). A possible 
mechanism for this is the type I IFN-dependent upregulation 
of the methyltransferase Setdb2, which can repress chemokines 
such as CXCL1 at the chromatin level (108). Also, influenza virus 
infection before or during MTb infection increases the severity 
of the MTb infection via type I IFN signaling (109). Interestingly, 
type I IFNs have been shown to inhibit inflammasome activa-
tion and IL-1 responses and increase IL-10 production (110). 
Altogether, this suggests that type I elicited during a lung viral 
infection makes it more possible for a subsequent bacterial infec-
tion to establish.
Lung Fungal infections
The role of type I IFNs during fungal infections has also been 
investigated using mice deficient in the IFNAR1. During a lung 
Pneumocystis infection, a decreased pro-inflammatory response 
was detected and even if the pathogen burden was the same, the 
clearance was delayed in Ifnar1−/− mice and this resulted in an 
exacerbated Th2 response and fibrosis (111). The lack of type I 
IFN signaling during Cryptococcus neoformans infection has been 
shown both to result in a decreased pathogen burden (112) and 
increased pathogen burden with increased death (113). However, 
both studies showed higher Th2 cytokine levels in the Ifnar1−/− 
mice after C. neoformans infection (112, 113). Thus, type I IFN 
responses during lung fungal infection are also part of driving the 
inflammatory response but it is still unclear in which magnitude 
or which mechanisms that are used.
SUMMARY
There are obvious benefits of type I IFNs during a lung viral infec-
tion as these cytokines have a vital cell-intrinsic antiviral effect 
limiting viral replication. However, the cell-extrinsic effects of 
type I IFNs are important during all lung infections as type I IFNs 
directly drive lung inflammation, most likely by amplifying pri-
mary signals initiated by other stimuli. When considering to use 
type I IFN as a potential antiviral agent, the immune-modulating 
effects during lung infections needs to be considered as the type 
I IFN response has to be tightly regulated so that a balance of 
beneficial (initiation of inflammation) and detrimental (immu-
nopathology) effects is achieved and gas exchange is not impaired.
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